FDA approves first drug to treat agitation associated with dementia due to Alzheimer’s
The U.S. Food and Drug Administration (FDA) on Thursday announced the supplemental approval of Rexulti (brexpiprazole) oral tablets for the treatment of agitation associated with dementia due to Alzheimer’s disease. Read More
Conferences
Science Briefs
Member Rewards
Earn points for contributing to market research. Redeem your points for merchandise, travel, or even to help your favorite charity.
Research Topics
Interact with an engaged, global community of your peers who come together to discuss their work and opportunities.
Connect
